Overview

Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
A study to evaluate the safety and anti-tumor activity of ASP3026 in patients with advanced malignancies (solid tumors).
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Inc